INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $208,506 | -36.3% | 4,006 | -22.6% | 0.00% | 0.0% |
Q2 2023 | $327,411 | +7.3% | 5,174 | -8.3% | 0.00% | 0.0% |
Q1 2023 | $305,125 | -54.8% | 5,643 | -64.2% | 0.00% | 0.0% |
Q4 2022 | $674,672 | +146.2% | 15,767 | +167.8% | 0.00% | 0.0% |
Q3 2022 | $274,000 | +29.9% | 5,888 | +59.5% | 0.00% | 0.0% |
Q2 2022 | $211,000 | -34.5% | 3,692 | -29.7% | 0.00% | 0.0% |
Q1 2022 | $322,000 | -9.6% | 5,252 | -22.8% | 0.00% | 0.0% |
Q4 2021 | $356,000 | +41.8% | 6,804 | +1.2% | 0.00% | 0.0% |
Q3 2021 | $251,000 | -15.5% | 6,722 | -7.6% | 0.00% | 0.0% |
Q2 2021 | $297,000 | +24.3% | 7,271 | +3.6% | 0.00% | 0.0% |
Q1 2021 | $239,000 | -31.3% | 7,015 | -36.0% | 0.00% | -50.0% |
Q4 2020 | $348,000 | -32.8% | 10,953 | -45.7% | 0.00% | -33.3% |
Q3 2020 | $518,000 | +18.0% | 20,176 | +18.0% | 0.00% | +50.0% |
Q2 2020 | $439,000 | +143.9% | 17,105 | +45.7% | 0.00% | +100.0% |
Q1 2020 | $180,000 | -45.5% | 11,736 | +42.3% | 0.00% | -50.0% |
Q3 2015 | $330,000 | – | 8,250 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |